This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

In the warning letter, the FDA alleged that Novo inadequately responded to observations made after an inspection carried out across January and February of 2025.

The agency cited 2 deaths and a case of suicidal ideation among incidents that were not submitted within required timeframes ...

A case series reports dysesthesia and allodynia in patients treated with semaglutide and tirzepatide, suggesting a possible dose related to sensory adverse effect.

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

GLP-1 obesity treatments may see wider access as key patents lapse.

The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between the years 2017 and 2024 reveals that Ozempic and Wegovy have both been ...

A new Cleveland Clinic study of nearly 8,000 patients found that people who stop popular GLP-1 weight-loss drugs often avoid ...

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call ...

How Long It Lasts and Tips to Reduce It This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Nausea is the most ...

Retrospective study finds link between blockbuster drugs and longer survival ...